Peter Wehrwein, Managing Editor

Results published in the journal Ophthalmology find no risk reduction from daily one-gram capsules of omega-3 fatty acids.

Leaders at UC Davis Health created an emerging therapies committee to review and prepare for the wave of treatments that cost millions of dollars.

After the onboarding of cell and gene therapy bogged using normal pharmacy and therapeutics (P&T) committee procedures, UC Davis Health set up an emerging therapeutics committee to streamline and speed up the process of delivery expensive cell and gene therapies.

Andel, principal of CommonHealth Solutions LLC, weighed in on potential strategies and challenges for Part D plans in navigating medication formulary limitations during catastrophic coverage phases in this second part of a two-part video series.

One result of the Inflation Reduction Act shifting a greater proportion the cost of drugs during the catastrophic phase of coverage to the Part D plans result may be narrower formularies.

Adam Colborn outlined four trends in state-level action on pharmacy benefit managers (PBMs) and drugs in an interview prior to this presentation at the annual meeting of Academy of Managed Care Pharmacy (AMCP) today.

Ross Margulies, J.D., M.P.H., a partner at the Foley Hoag law firm, discusses whether proposed transparency rules in the pharmacy benefit manager (PBM) legislation that Congress is considering might apply to the PBM-affiliated group purchasing organizations.

Ross Margulies, J.D., M.P.H., a partner at the Foley Hoag law firm, discusses proposals to “delink” what pharmacy benefit managers are paid from the price of drugs.

Ross Margulies, J.D., M.P.H., a partner at the Foley Hoag law firm, says there is broad agreement on transparency provisions and a ban on spread pricing in Medicaid.

The Access to Prescription Digital Therapeutics Act remains a top priority for the Academy of Managed Care Pharmacy (AMCP), according to Jennifer L. Mathieu, AMCP senior vice president of professional and government affairs.

Millennials (1981–1996), burdened by health problems and costly

CEO John Baackes is stepping down at the end of this year.

On specialty drugs, the Prime acquisition and vertical integration

In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.

Digital versions are coming on strong and this week the FDA cleared Eko Health’s algorithim-enhanced version that uses ECGs to screen for heart failure with reduced ejection fraction.

As we bring back Managed Healthcare Executive's "Meet the Board" podcast series, MHE welcomes its newest Editorial Advisory Board member Greg Baker, CEO of AffirmedRx.

Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.

Research underscores concerns that cost-sharing policies may contribute healthcare disparities.

People with higher incomes and those in health plans with health savings accounts benefit more than others, according to research results published this week in the Annals of Internal Medicine. The research also showed no increase in insulin use,

In this second part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein spoke with Ceci Connolly and Margaret "Meg" Murray about Medicare Advantage utilization and challenges, highlighting proposed CMS payment cuts and prior authorization issues.

High-deductible health plans are supposed to make patients smarter shoppers for healthcare services. But result reported in JAMA Network Open today add to the evidence that people with chronic conditions such as diabetes may put off care when deductibles are high, increasing the risk of complications and worsening of the disease.

In this first part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein kicks off our new podcast series "DC Roundtable," with guests Margaret "Meg" Murray, CEO of the Association of Community Affiliated Plans, and member of MHE's Editorial Advisory Board, and Ceci Connolly, president and CEO of the Alliance of Community Health Plans, for a discussion on healthcare policy issues.

Madrigal Pharmaceuticals is pricing Rezdiffra (resmetirom) at wholesale acquisition price of $47,400 per year.

The Incyte drug is headed for assessment in a phase 3 trial.

The 92-year-old "Star Trek" star said the skin cancer was treated surgically and with immunotherapy. It was apparently the first time he had discussed his melanoma in public.

Scabies, arsenic exposure and psychogenic pruritus are among the possibilities discussed in a poster presented at the annual meeting of the American Academy of Dermatology.

No safety signals emerged during the 26-month open label study of Vyjuvek (beremagene geperpavec), a topical gel approved as a treatment for dystrophic epidermolysis bullosa.

A "hit-it-hard, hit-it-early" strategy might eventually cure plaque psoriasis, said Andrew Blauvelt, M.D., MBA. Blauvelt presented promising data from his small study of high-dose Skyrizi (risankizumab), but the doses were not a cure and the disease "trickles back" albeit slowly, he said.

They range from skin conditions associated with sexually transmitted infections to acne to hair loss and removal for the alignment of appearance to gender identity.